TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8723849

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.0%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ropivacaine 0.5%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ropivacaine 0.75%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 125
Study: 2068825

Group type: EXPERIMENTAL
Intervention: 3 mg of prostaglandin E2 in an intravaginal gel
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 2 mg of prostaglandin E2 in a vaginal suppository
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both gel and suppository groups
Number of subjects: 37
Study: 6140239

Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Before varicocelectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: After varicocelectomy
Number of subjects: 0
Study: 31946656

Group type: EXPERIMENTAL
Intervention: Social proof
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Tangible rewards
Number of subjects: 143

Group type: COMPARATOR
Intervention: No extrinsic rewards (control group)
Number of subjects: 143
Study: 30379128

Group type: EXPERIMENTAL
Intervention: Manual phone tree
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Instant messaging application (IMA)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Short Message Service (SMS)
Number of subjects: 132
Study: 27530630

Group type: EXPERIMENTAL
Intervention: One-layer duct-to-mucosa pancreaticojejunostomy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Two-layer duct-to-mucosa pancreaticojejunostomy
Number of subjects: 114
Study: 24845870

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinyl palmitate per day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23088844

Group type: EXPERIMENTAL
Intervention: Primigravidae
Number of subjects: 3591

Group type: EXPERIMENTAL
Intervention: Multigravidae
Number of subjects: 3591
Study: 20147006

Group type: EXPERIMENTAL
Intervention: Trial participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open access users
Number of subjects: 0

Group type: COMPARATOR
Intervention: Registered open access users
Number of subjects: 0
Study: 18048991

Group type: EXPERIMENTAL
Intervention: Miglitol administered in two divided doses: 25 mg just before a meal and 25 mg at 15 min after the start of a meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Miglitol administered just before a meal (50 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Miglitol administered at 15 min after the start of a meal (50 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All intake schedules of miglitol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control: no miglitol
Number of subjects: 15
Study: 16230541

Group type: EXPERIMENTAL
Intervention: Full-dose intraoperative radiotherapy with electrons (ELIOT)
Number of subjects: 355
Study: 11473976

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 microg vaginally
Number of subjects: 10
Study: 10530131

Group type: EXPERIMENTAL
Intervention: Magnets
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bars (reference group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study: 8020670

Group type: EXPERIMENTAL
Intervention: Methotrexate (15 mg/wk)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 87
Study: 2489230

Group type: EXPERIMENTAL
Intervention: CyA/EPA + DHA (fish oil)
Number of subjects: 13

Group type: COMPARATOR
Intervention: CyA
Number of subjects: 13
Study: 807869

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 23
Study: 31657006

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (14,000 IU/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29620392

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)‐based guided self‐help (CBTgsh)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 40
Study: 28213632

Group type: EXPERIMENTAL
Intervention: 12-month weight gain prevention intervention including self-monitoring through mobile technologies and phone coaching
Number of subjects: 184

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 12-month weight gain prevention intervention
Number of subjects: 184
Study: 25819061

Group type: EXPERIMENTAL
Intervention: 100 mg anagliptin twice daily
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 200 mg anagliptin twice daily
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 23663488

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 100 μg, 1 spray/nostril QD for 4 weeks
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 21852106

Group type: EXPERIMENTAL
Intervention: Wedge group (n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supine group (n=40)
Number of subjects: 80
Study: 19081767

Group type: EXPERIMENTAL
Intervention: Serum Abeta(1-40)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Serum Abeta(1-42)
Number of subjects: 197
Study: 16793221

Group type: EXPERIMENTAL
Intervention: Interim Maintenance (IM)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 319
Study: 15336814

Group type: EXPERIMENTAL
Intervention: L-arginine enriched cardioplegia and non-cardioplegic reperfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no L-arginine)
Number of subjects: 40
Study: 11433695

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (oral prednisolone 40 mg/d for 1 month)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Various drug treatments (including corticosteroids, colchicine, propylthiouracil, etc.)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Monoclonal anti-TNFα antibodies
Number of subjects: 33
Study: 9408666

Group type: EXPERIMENTAL
Intervention: Independent assessment in RCTs of rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 8459988

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg orally 3 times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) and dexamethasone (8 mg) given orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study: 3517506

Group type: EXPERIMENTAL
Intervention: Diltiazem in crystalloid potassium cardioplegia (150 micrograms/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Crystalloid potassium cardioplegia
Number of subjects: 40
Study: 31092548

Group type: EXPERIMENTAL
Intervention: Low systemic arterial compliance (SAC) defined as ≤0.64 mL/m²
Number of subjects: 1641
Study: 29758560

Group type: EXPERIMENTAL
Intervention: Catheter rotation during withdrawal (study group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No catheter rotation during withdrawal (control group)
Number of subjects: 200
Study: 27498918

Group type: EXPERIMENTAL
Intervention: Modified bag-valve mask (BVM) with integrated internal handle
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard unmodified bag-valve mask (BVM)
Number of subjects: 70
Study: 25100366

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (100 μg daily if baseline 25[OH]D <50 nmol/L, or 50 μg daily if baseline 25[OH]D ≥50 nmol/L)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 22490854

Group type: COMPARATOR
Intervention: Fluorouracil plasma concentration <25 ng/ml
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Fluorouracil plasma concentration 25-35 ng/ml
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Fluorouracil plasma concentration >35 ng/ml
Number of subjects: 86
Study: 19403952

Group type: EXPERIMENTAL
Intervention: 7.5% maltodextrin solution
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 11
Study: 17166184

Group type: EXPERIMENTAL
Intervention: Steroid injection therapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy and steroid injection therapy combined
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watch and wait policy
Number of subjects: 0
Study: 15701436

Group type: EXPERIMENTAL
Intervention: Tacrolimus (n = 14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cyclosporine (n = 12)
Number of subjects: 26
Study: 12920254

Group type: EXPERIMENTAL
Intervention: Structured, progressive, physiologically based, therapist-supervised, in-home exercise program (36 sessions of 90 minutes over 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 10553497

Group type: EXPERIMENTAL
Intervention: Early onset pauciarticular juvenile chronic arthritis patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Systemic juvenile chronic arthritis patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 8890420

Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration prior to surgery
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration at the end of surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (saline infiltration)
Number of subjects: 70
Study: 1889273

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with norfloxacin, polymyxin E, and amphotericin B topically, and intravenous cefotaxime 500 mg three times a day for the first five days.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group 1 (no antibiotic prophylaxis)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group 2 (no antibiotic prophylaxis)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (group 3)
Number of subjects: 56
Study: 6405770

Group type: EXPERIMENTAL
Intervention: 9.2 mg of glyceryl trinitrate (GTN) cream (acute study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9.2 mg of glyceryl trinitrate (GTN) cream (1 h post-application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9.2 mg of glyceryl trinitrate (GTN) cream (chronic study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased dose of glyceryl trinitrate (GTN) cream (after 3 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (during the study)
Number of subjects: 0
Study: 3800816

Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-training group
Number of subjects: 100
Study: 30085130

Group type: EXPERIMENTAL
Intervention: Genetically higher BMI (each standard deviation increase of about 4.6 kg/m2)
Number of subjects: 2115

Group type: COMPARATOR
Intervention: Waist-to-hip ratio adjusted for BMI
Number of subjects: 2115
Study: 27088193

Group type: EXPERIMENTAL
Intervention: Double-wire sternal closure
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single-wire sternal closure
Number of subjects: 200
Study: 25691618

Group type: EXPERIMENTAL
Intervention: Renal denervation using the Symplicity system
Number of subjects: 998
Study: 23412547

Group type: EXPERIMENTAL
Intervention: Compression garments (COMP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Humidification therapy (HUM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive control (CON)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Electronic muscle stimulation (EMS)
Number of subjects: 11
Study: 21068681

Group type: EXPERIMENTAL
Intervention: High-speed power training at 40% of the 1-repetition maximum (1RM)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Traditional resistance training at 80% 1RM
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study: 18249201

Group type: EXPERIMENTAL
Intervention: Protein-rich meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fat-rich meal
Number of subjects: 30
Study: 16368318

Group type: EXPERIMENTAL
Intervention: MECC Jostra System
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 400
Study: 12688453

Group type: EXPERIMENTAL
Intervention: CON‐ECC (75% concentric and 25% eccentric)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ECC‐CON (75% eccentric and 25% concentric)
Number of subjects: 31

Group type: COMPARATOR
Intervention: CON (100% concentric)
Number of subjects: 31
Study: 10763950

Group type: EXPERIMENTAL
Intervention: IBS-QOL
Number of subjects: 0
Study: 8839294

Group type: EXPERIMENTAL
Intervention: Tridimensional Personality Questionnaire administered to social phobia patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (N=40)
Number of subjects: 47
Study: 1486247

Group type: EXPERIMENTAL
Intervention: Small-peptide diet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mixed diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Whole protein diet
Number of subjects: 6
Study: 4006485

Group type: EXPERIMENTAL
Intervention: Not applicable; trial was canceled
Number of subjects: 0
Study: 30945118

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 20 mg once daily (steady state) with lisinopril (20 mg single dose)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 20 mg once daily (steady state) with warfarin (25 mg single dose)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 20 mg once daily (steady state) with digoxin (500 μg single dose)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 20 mg once daily (steady state) with metformin (850 mg twice daily for 4 days)
Number of subjects: 84

Group type: COMPARATOR
Intervention: SNAC alone (300 mg single dose) with lisinopril, warfarin, digoxin, or metformin
Number of subjects: 84
Study: 30206820

Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (DMF)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 24177712

Group type: EXPERIMENTAL
Intervention: Aquatic therapy (n = 24, two months, five times/week)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waiting list control group (n = 25)
Number of subjects: 49
Study: 22569030

Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional laryngoscope
Number of subjects: 60
Study: 20299736

Group type: EXPERIMENTAL
Intervention: Dietary calorie intake during hospitalization (25 kcal/kg IBW)
Number of subjects: 144
Study: 19092257

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1,200 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15921686

Group type: EXPERIMENTAL
Intervention: Metformin pretreatment (1500 mg daily for 12 days, followed by clomiphene 150 mg daily for 5 days along with metformin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual treatment (clomiphene 150 mg daily for 5 days without metformin pretreatment)
Number of subjects: 80
Study: 11891671

Group type: EXPERIMENTAL
Intervention: Nemifitide (subcutaneous doses ranging from 18 to 320 mg)
Number of subjects: 100
Study: 10825058

Group type: EXPERIMENTAL
Intervention: Intravenous foscarnet (100 mg/[kg x 12 h])
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 42
Study: 8573554

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) at a dose of 800 mg/day
Number of subjects: 10
Study: 2616707

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 20 minutes
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waiting-period control condition
Number of subjects: 80
Study: 308146

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bencyclane
Number of subjects: 0
Study: 30904674

Group type: EXPERIMENTAL
Intervention: aIIV3
Number of subjects: 7532

Group type: COMPARATOR
Intervention: IIV3
Number of subjects: 7532
Study: 29988707

Group type: EXPERIMENTAL
Intervention: Enhanced physiotherapy care package (education, twice daily coached breathing exercises for a minimum of 2 days, and 30 minutes of daily supervised early rehabilitation for a minimum of five postoperative days)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard care physiotherapy (education, single session of coached breathing exercises, and daily early ambulation for 15 minutes)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Enhanced physiotherapy care package
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard care physiotherapy
Number of subjects: 288
Study: 26308708

Group type: EXPERIMENTAL
Intervention: Alfacalcidol at 1 μg/day
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Alendronate 35 mg/week
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Alfacalcidol plus alendronate
Number of subjects: 106

Group type: COMPARATOR
Intervention: Commencement of glucocorticoid therapy
Number of subjects: 106
Study: 25353174

Group type: EXPERIMENTAL
Intervention: Minocycline (200mg/d) + risperidone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo + risperidone
Number of subjects: 43
Study: 22738922

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 771

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 771
Study: 18716400

Group type: EXPERIMENTAL
Intervention: HEPA air cleaners
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham air cleaners
Number of subjects: 36
Study: 17277715

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 15093201

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant treatment
Number of subjects: 0
Study: 11476014

Group type: EXPERIMENTAL
Intervention: Silica-based, enamel-safe tartar control whitening dentifrice
Number of subjects: 291

Group type: COMPARATOR
Intervention: Marketed baking soda dentifrice control
Number of subjects: 291
Study: 11477860

Group type: EXPERIMENTAL
Intervention: Lentinan plus CO2 laser irradiation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Laser irradiation alone
Number of subjects: 36
Study: 7829908

Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg once a day for 3 days (cholera), 7 days (Salmonella enteritis), 5 days (other infectious enteritis)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fleroxacin 300 mg once a day for 3 days (cholera), 7 days (Salmonella enteritis), 5 days (other infectious enteritis)
Number of subjects: 143
Study: 2892770

Group type: EXPERIMENTAL
Intervention: Somatostatin-28 (SS-28) 100 micrograms/h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Somatostatin-14 (SS-14) 250 micrograms/h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 8
Study: 29789908

Group type: EXPERIMENTAL
Intervention: Two-phasic contrast injection (25mgI/kg/s for 12 seconds in 1st phase and 3.0 ml/s for 7 seconds in 2nd phase) with two axial scans using smart-coverage technique.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional protocol with contrast injection (25mgI/kg/s for 14 seconds) and helical/axial scanning.
Number of subjects: 60
Study: 26618662

Group type: EXPERIMENTAL
Intervention: Reamed tibial nails
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Unreamed tibial nails
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Reamed and unreamed tibial nails
Number of subjects: 1319
Study: 25135743

Group type: EXPERIMENTAL
Intervention: QVA149 110/50 μg
Number of subjects: 11404

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 11404

Group type: EXPERIMENTAL
Intervention: Glycopyrronium 50 μg
Number of subjects: 11404

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 11404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11404
Study: 22205617

Group type: EXPERIMENTAL
Intervention: roxatidine 75 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: omeprazole 20 mg
Number of subjects: 10
Study: 20061426

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17278943

Group type: EXPERIMENTAL
Intervention: Reciprocating Procedure Device (RPD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional Syringe
Number of subjects: 80
Study: 16596912

Group type: EXPERIMENTAL
Intervention: Racemic bupivacaine 0.5% with 1 : 200,000 epinephrine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 75% levobupivacaine and 25% dextrobupivacaine 0.5% with 1 : 200,000 epinephrine
Number of subjects: 22
Study: 11901047

Group type: EXPERIMENTAL
Intervention: BG9719 alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BG9719 plus furosemide
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BG9719 alone (2 lower doses)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Furosemide alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BG9719 plus furosemide (2 lower doses)
Number of subjects: 63
Study: 8552741

Group type: EXPERIMENTAL
Intervention: Allergic skin tests administered to one forearm
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline administered to the other forearm
Number of subjects: 10
Study: 2190865

Group type: EXPERIMENTAL
Intervention: Omeprazole (profound acid suppression)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (control)
Number of subjects: 0
Study: 39900

Group type: EXPERIMENTAL
Intervention: Melperone (Buronil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31764003

Group type: EXPERIMENTAL
Intervention: sublingual nifedipine
Number of subjects: 120

Group type: COMPARATOR
Intervention: control group
Number of subjects: 120
Study: 30739254

Group type: EXPERIMENTAL
Intervention: Ustekinumab (45/90 mg subcutaneous for psoriasis and PsA; 130 mg or weight-based dosing for CD)
Number of subjects: 6280
Study: 28122895

Group type: EXPERIMENTAL
Intervention: 21-gene recurrence score (RS)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Pathologic nodal status
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Tumor size
Number of subjects: 1065
Study: 28985917

Group type: EXPERIMENTAL
Intervention: Aromatherapy inhalation (sweet orange and lavender oil) for one month
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard hemodialysis treatment (control group)
Number of subjects: 62